In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone.

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone. Abstract Text:

Kazuki Hoshino,Kazue Inoue,Yoichi Murakami,Yuichi Kurosaka,Kenji Namba,Yoshinori Kashimoto,Saori Uoyama,Ryo Okumura,Saito Higuchi,Tsuyoshi Otani,

DC-159a is a new 8-methoxy fluoroquinolone that possesses a broad spectrum of antibacterial activity, with extended activity against gram-positive pathogens, especially streptococci and staphylococci from patients with community-acquired infections. DC-159a showed activity against Streptococcus spp. (MIC(90), 0.12 mug/ml) and inhibited the growth of 90% of levofloxacin-intermediate and -resistant strains at 1 mug/ml. The MIC(90)s of DC-159a against Staphylococcus spp. were 0.5 mug/ml or less. Against quinolone- and methicillin-resistant Staphylococcus aureus strains, however, the MIC(90) of DC-159a was 8 mug/ml. DC-159a was the most active against Enterococcus spp. (MIC(90), 4 to 8 mug/ml) and was more active than the marketed fluoroquinolones, such as levofloxacin, ciprofloxacin, and moxifloxacin. The MIC(90)s of DC-159a against Haemophilus influenzae, Moraxella catarrhalis, and Klebsiella pneumoniae were 0.015, 0.06, and 0.25 mug/ml, respectively. The activity of DC-159a against Mycoplasma pneumoniae was eightfold more potent than that of levofloxacin. The MICs of DC-159a against Chlamydophila pneumoniae were comparable to those of moxifloxacin, and DC-159a was more potent than levofloxacin. The MIC(90)s of DC-159a against Peptostreptococcus spp., Clostridium difficile, and Bacteroides fragilis were 0.5, 4, and 2 mug/ml, respectively; and among the quinolones tested it showed the highest level of activity against anaerobic organisms. DC-159a demonstrated rapid bactericidal activity against quinolone-resistant Streptococcus pneumoniae strains both in vitro and in vivo. In vitro, DC-159a showed faster killing than moxifloxacin and garenoxacin. The bactericidal activity of DC-159a in a murine muscle infection model was revealed to be superior to that of moxifloxacin. These activities carried over to the in vivo efficacy in the murine pneumonia model, in which treatment with DC-159a led to bactericidal activity superior to those of the other agents tested.

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone. Publishing Authors By Initials

K Hoshino,K Inoue,Y Murakami,Y Kurosaka,K Namba,Y Kashimoto,S Uoyama,R Okumura,S Higuchi,T Otani,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Antimicrobial agents and chemotherapy

VOLUME: 52

Page Numbers: 65-76

Journal Abbreviation: Antimicrob. Agents Chemother.

ISSN: 0066-4804

DAY: 15

MONTH: 10

YEAR: 2007

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 315061

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone.

AFFILIATION: Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan. hoshino.kazuki.d6@daiichisankyo.co.jp.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Antimicrob Agents Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone Related Publications

• Cardiac electrical dynamics: maximizing dynamical heterogeneity.
• Circulating hematopoietic stem cells in patients with neovascular age-related macular degeneration.
• Classification accuracy across multiple tests following item method directed forgetting.
• Enzymatic hydrolysis of gramicidin S.
• Evolution of the spin Hall effect in pt nanowires: size and temperature effects.
• Immediate tonsillectomy for peritonsillar abscess.
• In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone.
• Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities.
• Large spin accumulation in a permalloy-silver lateral spin valve.
• No association between the -3081A/T polymorphism in the norepinephrine transporter gene promoter and personality traits in healthy subjects.
• Paracellular absorption: a bat breaks the mammal paradigm.
• Studies of enzymatically active subfragments of myosin-adenosinetriphosphatase. III. Separation of two components.
• The effectiveness of a nurse-initiated intervention to reduce catheter-associated bloodstream infections in an urban acute hospital: an intervention study with before and after comparison.
• [A life of a nurse. 8. Observation of changes in American nursing education. (2)]
• [Allocation of nursing personnel]
• [Changing nursing duty and work analysis. Standardization of nursing and the current problems]
• [Discussion: life activities through nursing. 10. Creation of an ideal home for the aged utilizing the nursing experience]
• [Focusing on the gap between the ideal and the reality: on the postgraduate education]
• [International cooperation in medicine--an interview]
• [Observation of changes in American nursing education. Discussion. 1]
• [Overcoming the age of crisis]
• [Questions on continuity of nursing education]
• [Satisfaction in assisting the birth process. 30-year clinical practice in midwifery. A discussion]
• [Satisfaction in assisting the birth process. 6. 30 years of clinical practice in midwifery]
• [Staffing form perspective of personality of each staff member]
• [The depth of the emotions of the handicapped patients. A discussion with an assistant head of a facility for the severely handicapped]
• [The family. 11. Illness in the family]
• [The social environment to be created by the year 2000]
• [Toward reorganization of medicine and nursing]
• [Various problems concerning reassignment of nurses]